Loading clinical trials...

Time Restricted Eating on Cancer Risk | Clinical Trials | Clareo Health

COMPLETEDNA

Time Restricted Eating on Cancer Risk

The Effects of Time Restricted Feeding on AGE-RAGE Signaling in Women at High Risk for Breast Cancer

NCT05038137•Medical University of South Carolina

Summary

Participants will be randomly assigned to either the time restricted feeding group with a daily eating period of 8 hours or the control group with a daily eating period of greater than or equal to 12 hours. There are 2 in-person study visits to have blood, urine and vital signs collected and 8 remote or phone visits with a psychologist or dietician to assist with the eating schedule. The study will take last 3 1/2 months.

Eligibility

Age

40 - 67 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Age ≥ 40 and ≤ 67;
•Postmenopausal women (no menstrual periods in the preceding 12 or more months) with pre-diabetes (A1C 5.7-6.4% and/or fasting glucose 100-125 mg/dL). A1c lab and/or fasting glucose criteria will need to be met within 12 months of signing consent form, can be obtained from prior lab result or study prescreening testing;
•Own a smart phone with internet connection and capable of receiving and sending text messages and taking photographs;

Exclusion Criteria

•Tobacco use (current or within last 2 years);
•Active malignancy or history of cancer;
•History of known liver disease (by serology: aspartate aminotransferase or alanine aminotransferase ≥ 3 times above upper limit of normal determined by lab review, imaging or biopsy: determined by patient history);
•History of kidney disease (patient history and/or estimated glomerular filtration rate less than 45 mL/min/1.73m²);
•History of diabetes mellitus:
•History of cardiovascular disease (MI, CHF);
•Current prescription medication use for diabetes;
•Medication affecting glucose metabolism or appetite or immunosuppression;
•Dietary restrictions: currently following vegetarian or vegan dietary pattern;
•Currently following intermittent fasting or time restricted feeding pattern or use in the last 3 months;
+5 more criteria

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Key Dates

Start Date

May 4, 2022

Primary Completion Date

April 23, 2024

Completion Date

April 23, 2024

Last Updated

January 9, 2026

Enrollment

ACTUAL participants

Conditions

Pre-diabetesBreast CancerTime Restricted Feeding

Interventions

Time restricted feeding

BEHAVIORAL

Control

BEHAVIORAL

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGNA

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Time Restricted Eating on Cancer Risk

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer